Your browser doesn't support javascript.
loading
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
Budde, Lihua E; Sehn, Laurie H; Matasar, Matthew; Schuster, Stephen J; Assouline, Sarit; Giri, Pratyush; Kuruvilla, John; Canales, Miguel; Dietrich, Sascha; Fay, Keith; Ku, Matthew; Nastoupil, Loretta; Cheah, Chan Yoon; Wei, Michael C; Yin, Shen; Li, Chi-Chung; Huang, Huang; Kwan, Antonia; Penuel, Elicia; Bartlett, Nancy L.
Affiliation
  • Budde LE; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.
  • Sehn LH; Department of Medical Oncology, BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada; Department of Medicine, The University of British Columbia, Vancouver, BC, Canada.
  • Matasar M; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Schuster SJ; Lymphoma Translational Research, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
  • Assouline S; Division of Hematology, Jewish General Hospital, Montreal, QC, Canada.
  • Giri P; Department of Haematology, Royal Adelaide Hospital, Adelaide, SA, Australia.
  • Kuruvilla J; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Canales M; Servicio de Hematología, Hospital Universitario La Paz, Madrid, Spain.
  • Dietrich S; Department of Internal Medicine V: Hematology, Oncology and Rheumatology, Heidelberg University, Heidelberg, Germany.
  • Fay K; Department of Haematology, Royal North Shore Hospital, Sydney, NSW, Australia; Department of Haematology, St Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia.
  • Ku M; Department of Haematology, St Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia.
  • Nastoupil L; Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX, USA.
  • Cheah CY; Linear Clinical Research, Sir Charles Gairdner Hospital, Perth, WA, Australia; Lymphoma Translational Research, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; Department of Haematology, The University of Western Australia, Perth, WA, Australia.
  • Wei MC; Genentech, San Francisco, CA, USA.
  • Yin S; Genentech, San Francisco, CA, USA.
  • Li CC; Genentech, San Francisco, CA, USA.
  • Huang H; F Hoffmann-La Roche, Mississauga, ON, Canada.
  • Kwan A; Genentech, San Francisco, CA, USA.
  • Penuel E; Genentech, San Francisco, CA, USA.
  • Bartlett NL; Division of Oncology, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA. Electronic address: nbartlet@wustl.edu.
Lancet Oncol ; 23(8): 1055-1065, 2022 08.
Article in En | MEDLINE | ID: mdl-35803286
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Follicular / Antibodies, Bispecific / Neoplasm Recurrence, Local / Antineoplastic Agents Type of study: Clinical_trials Limits: Humans Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2022 Document type: Article Affiliation country: United States Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Follicular / Antibodies, Bispecific / Neoplasm Recurrence, Local / Antineoplastic Agents Type of study: Clinical_trials Limits: Humans Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2022 Document type: Article Affiliation country: United States Country of publication: United kingdom